Skip to main content
. 2021 Dec 1;12:7004. doi: 10.1038/s41467-021-27309-1

Fig. 3. Induction of non-obese NAFLD by GP73 is highly dependent on its GAP activity.

Fig. 3

a–g Plasma levels of LDL (a), TGs (b), CHO (c), ALT (f), and AST (g); hepatic levels of TGs (d), and CHO (e) in AAV-V-(Vector), AAV-GP73-(GP73), or AAV-GP73-RQ(GP73-RQ)-injected mice fed a regular diet for 4.5 months (n = 6 per group). Differences between the three groups were evaluated using one-way ANOVA and Bonferroni’s post hoc analysis. Data are presented as mean ± SEM. ns, no statistical significance; *P < 0.05; **P < 0.01; ***P < 0.001. h–j Glucose levels in blood samples from 6 h-fasted AAV-V-, AAV-GP73-, or AAV-GP73-RQ-injected mice at 2 (h), 3 (i), and 4 (j) months after injection (n = 6 per group). Differences between the three groups were evaluated using one-way ANOVA and Bonferroni’s post hoc analysis. Data are presented as mean ± SEM. ns, no statistical significance; *P < 0.05; **P < 0.01. k Glucose tolerance test (GTT) results for AAV-V-, AAV-GP73-, or AAV-GP73-RQ-injected mice at 4.5 months after injection (n = 6 per group). Differences between the three groups were evaluated using two-way ANOVA and Bonferroni’s post hoc analysis. Data are presented as mean ± SEM. ns, no statistical significance; ***P < 0.001.